Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Koji Tanabe currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, ensuring that each case is evaluated by a different person. Both of these pending office actions are situated within 1 distinct art unit, showing a concentrated technical classification for the portfolio.
PYLA, EVELYN Y is the busiest examiner for this portfolio, currently responsible for 1 pending office action. This 1 action is the highest number assigned to any single examiner for these cases. The distribution of 2 pending office actions across 2 distinct examiners within 1 distinct art unit means that practitioners will encounter two different examination styles for very similar technology. This arrangement requires a strategy that accounts for the individual preferences of 2 distinct examiners, even though the cases reside in the same 1 distinct art unit. The 2 pending office actions represent the total active workload for the company in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PYLA, EVELYN Y | 1 | 55.7% | +47.1% |
| RIGA, MICHAEL ANGELO | 1 | 57.1% | +61.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258778 | METHOD FOR PRODUCING OLIGODENDROCYTES | RIGA, MICHAEL ANGELO | 72d overdue |
| 18868650 | METHOD FOR PRODUCING STEM CELLS AND METHOD FOR PRODUCING GAMMA DELTA T CELLS | PYLA, EVELYN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258778 | METHOD FOR PRODUCING OLIGODENDROCYTES | RIGA, MICHAEL ANGELO | 72d overdue |
| 18868650 | METHOD FOR PRODUCING STEM CELLS AND METHOD FOR PRODUCING GAMMA DELTA T CELLS | PYLA, EVELYN Y | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868650 | METHOD FOR PRODUCING STEM CELLS AND METHOD FOR PRODUCING GAMMA DELTA T CELLS | PYLA, EVELYN Y | — | §102§103 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18258778 | METHOD FOR PRODUCING OLIGODENDROCYTES | RIGA, MICHAEL ANGELO | 1634 | §102§103 | Final Rejection | 72d overdue | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial